"Pharmacogenomics of Chemotherapeutic-Induced Neurotoxicities"

M. Eileen Dolan, PhD
Professor of Medicine
Deputy Director,
University of Chicago Comprehensive Cancer Center
The University of Chicago

LEARNING OBJECTIVES:
Upon completion of this activity, participants should be able to:

1. Describe considerations in designing optimal pharmacogenomic study to identify genetic variants associated with chemotherapeutic induced toxicities.
2. Describe incidence and severity of neurotoxicities following treatment with cisplatin and radiation.
3. Define clinical and modifiable risk factors associated with cisplatin and radiation induced hearing loss and tinnitus.

Speaker Disclosure:
Dr. Dolan has disclosed that she has no relevant financial relationships. No one else in a position to control content has any financial relationships to disclose. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. All relevant financial relationships have been mitigated.

Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit: The University of Florida College of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Section # 2099